Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074985 | 1.00 | IL1B (0.37) | IL1BPIM1PIM2 | |
| SCHEMBL31491349 | 0.88 | IL1B (0.35) | IL1BPIM1PIM2 | |
| SCHEMBL516879 | 0.88 | IL1B (0.35) | IL1BPIM1PIM2 | |
| SCHEMBL590224 | 0.88 | IL1B (0.35) | IL1BPIM1PIM2 | |
| SCHEMBL8058366 | 0.83 | IL1B (0.38) | IL1BPIM1PIM2 | |
| SCHEMBL8047905 | 0.79 | GPR119 (0.32) | — | |
| SCHEMBL12887360 | 0.79 | IL1B (0.37) | IL1BPIM1PIM2 | |
| SCHEMBL12892580 | 0.79 | IL1B (0.32) | IL1BPIM1PIM2 | |
| SCHEMBL10283466 | 0.79 | PDE4D (0.34) | IL1BPIM1PIM2 | |
| SCHEMBL12879556 | 0.79 | IL1B (0.32) | IL1BPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610258-B1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | POUZET PASCALE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108534-A1 | Dihydrothienopyrimidines for the treatment of inflammatory Diseases | DPYD, DHFR, TPMT | IL1B 98/4885PIM1 3532/4885PIM2 3914/4885 |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PDE4A, PDE12, PDE3B | IL1B 1061/4885PIM1 2445/4885PIM2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.